Biocryst Pharmaceuticals (BCRX) Invested Capital (2010 - 2026)

Biocryst Pharmaceuticals has reported Invested Capital for 17 years, with the latest figure at -$551.4 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 23.14% year-over-year to -$551.4 million; the trailing twelve-month figure through Mar 2026 stood at -$551.4 million (down 23.14% YoY), and the FY2025 full-year result was -$116.4 million, up 75.34% from the prior year.
• Invested Capital for Q1 2026 stood at -$551.4 million, down from -$116.4 million in the prior quarter.
• The five-year high for Invested Capital was -$10.3 million in Q3 2022, with the low at -$551.4 million in Q1 2026.
• Historically, Invested Capital has averaged -$310.6 million across 5 years, with a median of -$411.0 million in 2023.
• Annual changes were most pronounced in 2022 — Invested Capital jumped 93.01% — and 2023, when it slumped 3896.75%.
• Biocryst Pharmaceuticals' Invested Capital stood at -$292.0 million in 2022, then plunged by 54.5% to -$451.1 million in 2023, then dropped by 4.63% to -$472.0 million in 2024, then soared by 75.34% to -$116.4 million in 2025, then sank by 373.74% to -$551.4 million in 2026.
• The last three Invested Capital figures came in at -$551.4 million (Q1 2026), -$116.4 million (Q4 2025), and -$384.7 million (Q3 2025), per Business Quant data.